hdr isap

Polymyxin presentations 2013

Program for the 1st International Conference on Polymyxins
with links to the presentations

Thursday 2 May 2013

8:15 – 9:15

Registration

9:15 – 10:00

Chairs
Roger Nation
Jian Li
SESSION 1: Welcome, program overview and introduction to the polymyxins

· Key features of the polymyxins
Roger Nation (30 min)

10:00 – 10:30

Morning tea, poster viewing and networking

10:30 – 12:30

Chairs

David Paterson

Otto Cars

SESSION 2: The use of polymyxins in clinical practice

· Establishing the clinical need for polymyxins
David Paterson (25 min)

· Clinical outcomes in polymyxin studies: what are the challenges?
Fernanda Silveira (15 min)

· Are polymyxins effective? A meta-analysis of polymyxin use
Mical Paul (20 min)

· Snapshots of polymyxin use around the world:
12:30 – 13:45

Lunch, poster viewing and networking

13:45 – 15:45

Chairs

John Turnidge

Dennis Dixon

SESSION 3: Towards optimized dosing of intravenous colistin and polymyxin B

·  Critical preclinical PK/PD information
Vincent Tam (15 min)

·  Intravenous polymyxins in critically-ill patients: how can we fit the dose to the patient?

    - Importance of the loading dose: CMS vs polymyxin B     

Lena Friberg (15 min)

     - Selection of individualized maintenance doses for various categories of patients: CMS vs polymyxin B    

Roger Nation (30 min)

· Dosing in other special patient populations
Helen Giamarellou (20 min)

· Risk factors for nephrotoxicity
Alan Forrest (10 min)

·  Managing patients with declining kidney function and other adverse effects
Visanu Thamlikitkul (20 min)

15:45 – 16:15

Afternoon tea, poster viewing and networking

16:15 – 18:00

Chairs

Keith Kaye

Ursula Theuretzbacher

SESSION 4: What is the role of inhaled polymyxins for treatment of respiratory tract infections?

· Inhaled polymyxins: what can we learn from pulmonary delivery of other antibiotics?
Mike Dudley (20 min)

· Pulmonary disposition of polymyxins
William Couet (20 min)

·  Inhalational +/- intravenous administration of polymyxins for treatment of VAP
Helen Giamarellou (25 min)

· Use of polymyxins in patients with cystic fibrosis
Niels Høiby (25 min)

18:00 – 19:30

Reception on the Terrace

Friday 3 May 2013

9:00 – 11:00

Chairs

Brian Tsuji

Fernanda Silveira

SESSION 5: Polymyxins: mono-therapy or a combination?

· Preclinical approaches: What is important – synergy or activity of combinations?
Brian Tsuji (20 min)

· Translational approaches to inform selection of rational combinations for patients
Juergen Bulitta (20 min)

· Clinical trials of monotherapy versus combinations
o   Colistin/fosfomycin      Visanu Thamlikitkul (20 min)
o   Colistin/rifampicin        Claudio Viscoli (20 min)
o   Colistin/carbapenems  Keith Kaye and Johan Mouton (10 min each)

11:00 – 11:30

Morning tea, poster viewing and networking

11:30 – 12:30

Chairs

John Turnidge

Johan Mouton

SESSION 6: Susceptibility and breakpoints

· In vitro susceptibility testing: what are the critical issues?
John Turnidge (25 min)

· Polymyxin breakpoints: what needs attention?
Johan Mouton (25 min)

12:30 – 13:45

Lunch, poster viewing and networking

13:45 – 15:00

 

 

Chairs

Robert Bonomo

Irene Plank

SESSION 7: Mechanisms of activity, resistance and nephrotoxicity: how understanding may be used advantageously

· Mechanisms of antibacterial activity
Brian Tsuji (20 min)

· Mechanisms of resistance
Robert Bonomo (20 min)

· Bacterial biofilm and resistance
Niels Høiby (15 min)

· Mechanisms of nephrotoxicity
Jian Li (15 min)

15:00 – 15:30

Afternoon tea, poster viewing and networking

15:30 – 16:30

 

 

Chairs

Otto Cars

Vincent Tam

 

SESSION 8: Oral presentations of selected abstracts

· Abstract O-1
Murat Dizbay (8 min)

· Abstract O-2
Claudio Viscoli (8 min)

· Abstract O-3
Luisa Sorlí (8 min)

· Abstract O-4
Jason Pogue (8 min)
16:30 – 17:30

 
 

 


Chair

David Paterson

SESSION 9: Colistin and polymyxin B: are they peas in a pod or chalk and cheese?

A lively, entertaining and most importantly informative debate between two teams in which colistin and polymyxin B will be compared and contrasted. Might one have advantages over the other in regard to various considerations? The audience will have an opportunity to vote.

The topics are:

· The ability to achieve ‘appropriate’ plasma concentrations
Vincent Tam (Poly B team) vs John Turnidge (CMS team)

· Targeting specific infections (UTI, respiratory, CNS)
Matti Karvanen (Poly B team) vs William Couet (CMS team)

· Clinical effectiveness and adverse effects
Alexandre Zavascki (Poly B team) vs Keith Kaye (CMS team)

18:30 –

Conference dinner

Saturday 4 May 2013

9:00 – 10:00

 


Chairs

Ursula Theuretzbacher William Couet

SESSION 10: Oral presentations of selected abstracts

· Abstract O-5
William Couet (8 min)

· Abstract O-6
Olivia Bargiacchi (8 min)

· Abstract O-7
Teysir Halaby (8 min)

· Abstract O-8
Gunther Kern (8 min)

10:00 – 10:30

Chairs

Dennis Dixon
Irene Plank


SESSION 11: EU and NIH programs facilitating antibacterial resistance research

·  Outlines of the key programs of the NIH and EU will be provided
Irene Plank and Dennis Dixon

10:30 – 11:00

Morning tea and networking

11:00 – 12:30

 
 

Chairs

Roger Nation
Jian Li


SESSION 12: The Prato Polymyxin Consensus

· Key topics and issues identified during the preceding symposia will be brought to this session and discussed by a panel, with ample opportunity for input from the audience

· Recommendations will be made on aspects impacting the future clinical use of polymyxins and high-priority areas for research, and the audience will be asked to vote on whether they do or don’t support the recommendations

· The outcome will be the basis of the Prato Polymyxin Consensus which will summarize high-priority areas requiring attention

Panel members:

David Paterson
Johan Mouton
Keith Kaye
Ursula Theuretzbacher
Brian Tsuji
Mike Dudley
John Turnidge

· The 2nd International Polymyxin Conference: when and where?

· Conference close

12:30 – 13:30

Lunch and departure to airport or other

Publications

Some selected major PK/PD publications

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus: RL Nation, J Li, O. Cars, W. Couet, MN Dudley, KS Kaye, JW Mouton, DL Paterson, VH Tam, U. Theuretzbacher, BT Tsuji, JD Turnidge.
The Lancet Infectious Diseases, Early Online Publication, 21 October 2014
Please sign in and read the Full article

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

Jason A Roberts, Mohd H Abdul-Aziz, Jeff rey Lipman, Johan W Mouton, Alexander A Vinks, Timothy W Felton, William W Hope, Andras Farkas, Michael N Neely, Jerome J Schentag, George Drusano, Otto R Frey, Ursula Theuretzbacher, Joseph L Kuti, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases

Lancet Infect Dis April 2014
Please sign in and read the Full article

Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Gonzalez D, Schmidt S, Derendorf H.
Clin Microbiol Rev. 2013 Apr;26(2):274-88.

Please log in to see the full article

New EMA guideline for antimicrobial development.

Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL.
Lancet Infect Dis. 2012 Apr;12(4):265-6.

Please log in to see the full article
Saving Lives with Optimal Antimicrobial Chemotherapy.

Drusano GL, Lodise TP
Clin Infect Dis 2012 Oct 16

Please log in to see the full article

Predicting bacterial fitness cost associated with drug resistance.

Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH.
J Antimicrob Chemother. 2012 Apr;67(4):928-32.

Fundamentals of Population Pharmacokinetic Modelling: Modelling and Software.

Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH.
Clin Pharmacokinet. 2012 Aug 1;51(8):515-25.

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.

Mouton JW, Brown DF, Apfalter P, Cantón R, Giske CG, Ivanova M, MacGowan AP, Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G.
Clin Microbiol Infect. 2012 Mar;18(3):E37-45

Colistin pharmacokinetics: the fog is lifting.

Couet W, Grégoire N, Marchand S, Mimoz O.
Clin Microbiol Infect. 2012 Jan;18(1):30-9.

Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.

Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J.
Drug Resist Updat. 2011 Apr;14(2):107-17

The effect of critical illness on drug distribution.

Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H.
Curr Pharm Biotechnol. 2011 Dec;12(12):2030-6.

Protein binding: do we ever learn?

Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U.
Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74.

Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Nielsen EI, Cars O, Friberg LE.
Antimicrob Agents Chemother. 2011 Oct;55(10):4619-30

In vitro pharmacodynamic models to determine the effect of antibacterial drugs.

Gloede J, Scheerans C, Derendorf H, Kloft C.
J Antimicrob Chemother. 2010 Feb;65(2):186-201.

Significance of protein binding in pharmacokinetics and pharmacodynamics.

Schmidt S, Gonzalez D, Derendorf H.
J Pharm Sci. 2010 Mar;99(3):1107-22.

A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Dalhoff A, Ambrose PG, Mouton JW.
Infection. 2009 Aug;37(4):296-305.

Back to the future: using aminoglycosides again and how to dose them optimally.

Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A.
Clin Infect Dis. 2007 Sep 15;45(6):753-60

 

Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL.
Clin Infect Dis. 2007 Jan 1;44(1):79-86.

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
Johan W. Mouton, Michael N. Dudley, Otto Cars, Hartmut Derendorf and George L. Drusano
Journal of Antimcrobial Chemotherapy (2005) 55: 601-607

Activities

Please select from the menu
  • President

    (2018-2020)

    Brian Tsuji, PharmD
    University of Buffalo, New York, USA
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Treasurer

    (2018-2020)

    Zack Bulman, PharmD
    The University of Illinois, Chicago, USA
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • President-elect

    (2018-2020)

    Sebastian Wicha, PhD
    University of Hamburg, Germany
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Council

    (2018-2020)

    • Roger Nation, PhD; Monash University, Sydney, Australia
    • Hartmut Derendorf, PhD; University of Florida, Gainesville, FL, USA
    • Lena Friberg, PhD; Uppsala University, Sweden
    • Elizabeth Lakota, PharmD; Institute of Clinical Pharmacodynamics, Albany, NY, USA
    • Justin Lenhard, PharmD; California Northstate University, Elk Grove, CA, USA
    • Elisabet Nielsen, PhD; Uppsala University, Sweden
    • Ursula Theuretzbacher, PhD; Center for Anti-Infective Agents, Vienna, Austria
    • Markus Zeitlinger, MD; Medical University of Vienna, Vienna, Austria
  • Past-presidents

    (1991-2018)

    • William A. Craig, MD, Madison, WI (Founding president; president -1991-1994)
    • Otto Cars, MD, Uppsala, Sweden (1994-1996)
    • Mike N. Dudley, PharmD, San Diego, CA (1996-1998)
    • Paul M. Tulkens, MD, PhD, Brussels, Belgium (1998-2000)
    • George L. Drusano, MD, Gainesville, Fl (2000-2002)
    • Johan W. Mouton, MD, Nijmegen, The Netherlands (2002-2004)
    • Hartmut Derendorf, PhD, Gainesville, Fl (2004-2006)
    • Fritz Sörgel, PhD, Nürnberg, Germany (2006-2008)
    • David Andes, MD, Madison, WI (2008-2010)
    • Alasdair P. MacGowan, PhD, Bristol,UK (2010-2012)
    • Paul Ambrose, PharmD, FIDSA, Latham, NY, USA (2012-2014)
    • Ursula Theuretzbacher, PhD, Vienna, Austria (2014-2016)
    • Roger Nation, PhD, Sydney, Australia (2016-2018)

Disclaimer

This website is financed, owned and operated by the Society of Anti-Infective Pharmacology, a registered non-profit organization in the US.

Copyright: ISAP maintains the copyright for all material on the ISAP website with all rights reserved. Any copyright violation may result in ISAP protecting its rights.

Disclaimer:

ISAP cannot provide any guarantees and cannot be held liable for any errors, inaccuracies or incompleteness of any information given on this website by officers or employees of ISAP or any other third party the views and opinions expressed by individual authors of articles, presentations or discussion/opinion papers etc. do not necessarily reflect those of ISAP.

ISAP links to many websites created and maintained by other public and/or private organizations as a service to the users. The presence of a link is not an ISAP endorsement of the site. ISAP is not responsible for the information collection practices of non-ISAP sites.

ISAP is not liable in any way and without any limit towards any party for any kind of damage, loss or harm that might be caused by visiting this website. It is not ISAP’s responsibility to make sure that your system is free of viruses and any other kind of possibly harmful issues. ISAP does not guarantee that any other site you obtain access to through this website is free of any such potentially harmful items.

  • 1
  • 2